Large-cap Health Care company Elevance Health has moved -0.7% so far today on a volume of 271,444, compared to its average of 2,487,417. In contrast, the S&P 500 index moved -0.0%.
Elevance Health trades -13.21% away from its average analyst target price of $370.44 per share. The 18 analysts following the stock have set target prices ranging from $297.0 to $507.0, and on average have given Elevance Health a rating of buy.
Anyone interested in buying ELV should be aware of the facts below:
-
Elevance Health's current price is 0.4% above its Graham number of $320.15, which implies that at its current valuation it does not offer a margin of safety
-
Elevance Health has moved -37.8% over the last year, and the S&P 500 logged a change of 16.3%
-
Based on its trailing earnings per share of 23.57, Elevance Health has a trailing 12 month Price to Earnings (P/E) ratio of 13.6 while the S&P 500 average is 29.3
-
ELV has a forward P/E ratio of 9.2 based on its forward 12 month price to earnings (EPS) of $34.95 per share
-
Its Price to Book (P/B) ratio is 1.65 compared to its sector average of 3.19
-
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States.
-
Based in Indianapolis, the company has 104,200 full time employees and a market cap of $72.4 Billion. Elevance Health currently returns an annual dividend yield of 2.1%.
